Skip to main content
TRIGYN AWARDED “MEDICAL” OPEN SOURCE, AGILE METHODOLOGY, TABLET PROJECT

TRIGYN AWARDED “MEDICAL” OPEN SOURCE, AGILE METHODOLOGY, TABLET PROJECT

Trigyn announced today that it has entered into an agreement with a multi-billion dollar US based Life Sciences Company to develop a state-of-the-art, tablet based, open source system for the “Medical” products division of its client. The development will be performed using the Agile Project Management methodology. The services for this effort will be carried out by Trigyn’s Development Center located in Mumbai, India. Trigyn’s DC has been in operation for the past 25 years. Trigyn’s DC facility is CMMI Level 3 and ISO 9001:2008 Certified. This award follows the successful development and implementation of our client’s state-of-the-art open source tablet based sales tool, which has been deployed in the US, EU and Asia-Pac regions.

Recent News

Launch of e-Migrate Portal and App will Streamline Overseas Employment

Launch of e-Migrate Portal and App will Streamline Overseas Employment

Launch of e-Migrate Portal and App will Streamline Overseas Employment

Trigyn Announces AI Innovation and Delivery Center

Trigyn Announces AI Innovation and Delivery Center

Trigyn Announces AI Innovation and Delivery Center

Trigyn Awarded Baltimore County, Maryland Temporary Staffing Contract

Trigyn Awarded Baltimore County, Maryland Temporary Staffing Contract

Trigyn Awarded Baltimore County, Maryland Temporary Staffing Contract

Trigyn Technologies Inc. is a wholly owned subsidiary of Trigyn Technologies Ltd. collectively, we are committed to providing transparent and timely information to all of the stakeholders who have put their trust in us.

For any media-related inquiries, we encourage you to use our “Contact Us” form, available by clicking here.

For information about investment-related topics or stock information, please visit our Investors page by clicking here. For Investor or stock related inquiries, please use the contact information specified on the Investors page.

Thank you for your interest in Trigyn.